Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1

Conditions

Solid Tumor, Adult 1Neoplasm Metastasis 1Colorectal Neoplasms 1

Interventions

Cisplatin 3205Cyclophosphamide 3200Carboplatin 2979Radiotherapy 2790Paclitaxel 2720Gemcitabine 2573pembrolizumab 2388Bevacizumab 2210Docetaxel 2200Fluorouracil 1851Capecitabine 1834Oxaliplatin 1742Dexamethasone 1606Nivolumab 1581Doxorubicin 1503Rituximab 1489Magnetic Resonance Spectroscopy 1391Etoposide 1346Irinotecan 1248Leucovorin 1227Drug Therapy 1205Cytarabine 1131Pemetrexed 1078fludarabine 1065Specimen Handling 1021Vincristine 966Trastuzumab 946Cetuximab 945Prednisone 943Lenalidomide 938

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
EBI-005 × Clear all
NCT06634875 2026-03-31

Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)

Buzzard Pharmaceuticals

Phase 2 Recruiting
20 enrolled
Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT04121442 2024-08-06

Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors

Buzzard Pharmaceuticals

Phase 1/2 Completed
15 enrolled
Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡